Frequently Asked Questions

​

Operational History: Stramsen Biotech Inc. has been operational since November 2020, with a tenure exceeding three years in the biopharmaceutical industry.

​

Corporate Structure: The company is incorporated in the state of Delaware, a jurisdiction known for its business-friendly legal framework.

​

Research Expertise: Our scientific team boasts a combined total of over 100 years of research experience, positioning us at the forefront of plant-based pharmaceutical development.

 

Financial Status: Currently, the company is in a pre-revenue phase, typical of biopharmaceutical firms in the research and development stage.

 

Investment Portfolio: Stramsen Biotech Inc. has secured venture capital backing from GEM Global Yield, with a committed investment of $25 million contingent upon public listing.

 

Geographical Presence: Our headquarters are strategically located in Houston, Texas, a burgeoning hub for biotechnology innovation.

 

Regulatory Compliance: We have successfully filed for Regulation A  with the Securities and Exchange Commission (SEC). We have engaged Nasdaq Private Market as our designated broker-dealer and are in the process of obtaining the requisite legal opinion.

 

Initial Public Offering (IPO) Strategy: The company is closely monitoring market conditions with the intention of filing an S-1 prospectus with the SEC by the conclusion of fiscal year 2025.

 

Investment Banker: We are talking to several potential partners.

 

Market Maker: A leading Market marker has shown willingness to partner with us.

 

Current Shareholders : Our Cap table has over 470 shareholders. 
 

Financial Infrastructure: We are actively seeking underwriters for our prospective IPO and are in discussions with a leading market maker in the U.S. public markets.

 

Additional Regulatory Compliance: Stramsen Biotech Inc. has filed the necessary Regulation D documentation with the SEC, further solidifying our regulatory standing.

 

Strategic Alliances: We are in active discussions regarding potential collaborations with several prestigious institutions.

​

​

 

 

​